Previously dba Avidity NanoMedicines LLC, Avidity Biosciences is a biopharmaceutical company focused on advancing a new class of precision medicines Antibody-siRNA Conjugates (ASC). The latter are designed to combine the strengths of monoclonal antibodies and siRNA-based therapeutics - drawing down on the best features of both antibody-drug conjugates and nucleic acid-based medicines and utilizing nano-scale self-assembly to create a transformative approach to the treatment of cancer and other serious diseases. Although nucleic acid-based therapeutics have demonstrated success in targeting the liver, systemic bioavailability remains a challenge. The technology under development by Avidity combines the potency and specificity of biologics with nanoparticle technology and precise molecular targeting to create a platform that can be tailored to specific tumors.
